newcelx.comCrawled Oct 25, 2026
NewcelX Powerful Technology Synergies: Combining the core competencies of both technologies in order to create a holistic solution for comprehensive diabetes management.
NewcelX pipeline
Press Releases & Media Coverage
NewCelX Home
Cookie Policy for Newclex Ltd.
NewCelX Ltd outlines how user data is collected and protected in its Privacy Policy.
Newclex Ltd. Terms and Conditions
NewcelX Ltd secures a **$1.4 million private placement** to fund its **Type 1 diabetes research program**. The capital injection supports ongoing development of potential therapies targeting the autoimmune condition. The company specializes in regenerative medicine approaches for diabetes treatment.
Aug 2026The Globe and MailNews article
NewcelX secures a patent in Brazil for its **NCEL-101** therapy, a stem-cell-derived treatment for **type 1 diabetes**, using proprietary **cell selection and enrichment technology**. The patent, issued by the Brazilian Patent and Trademark Office, strengthens the company’s global intellectual property portfolio. NewcelX specializes in regenerative medicine therapies targeting unmet clinical needs.
Jul 2026BioSpaceNews article
NewcelX partners with Eledon Pharmaceuticals to develop **NCEL-101**, a stem-cell-derived therapy targeting **Type 1 Diabetes**. The collaboration aims to accelerate clinical progress for the experimental treatment. NewcelX specializes in stem-cell therapies and operates as a clinical-stage biotech company.
Mar 2026PR NewswireNews article
NewcelX Ltd. emerges as the merged entity of NLS Pharmaceutics Ltd. and Kadimastem Ltd., now trading on the Nasdaq. The merger finalizes a deal first announced in November 2024, with the new company officially operational as of October 31, 2025. The combined entity retains the branding of NewcelX, reflecting its focus on pharmaceutical advancements from both predecessors.
Nov 2025S-GENews article